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eta-Blockers
n the Treatment
f Aortic Regurgitation
New Opportunity?*
ri Elkayam, MD
os Angeles, California
hronic aortic regurgitation (AR) is associated with left
entricular (LV) volume overload that can lead to LV
ilation, increase in wall stress, LV hypertrophy, and eventu-
lly, to symptomatic heart failure and death (1,2). Aortic valve
eplacement (AVR) is the only proven beneficial treatment, but
t is usually reserved for patients with advanced disease and
erformed after the development of symptoms and/or signifi-
ant alteration in ventricular size or systolic function (2). For
ack of adequate, large-scale, randomized clinical trials, there is
o established medical treatment for patients with chronic
evere AR prior to or after surgery (3).
See page 452
Because of the demonstrated favorable acute effect of vaso-
ilators in reducing regurgitant volume and improving cardiac
erformance in AR (4–6), an attempt has been made to use
hese drugs in the treatment of chronic AR. A recent review by
ahajerin et al. (7) has provided an excellent summary of the
vailable data on the effect of vasodilator therapy in a total of
44 patients included in 10 prospective, randomized clinical
rials that evaluated this form of therapy in asymptomatic
atients with chronic AR with at least moderate severity and
ormal LV function. The drugs included were nifedipine,
ydralazine, and angiotensin-converting enzyme (ACE)
nhibitors. Although most studies demonstrated a favorable
ffect on some hemodynamic and/or structural parameters,
ther studies did not. The effect on clinical outcome was
eported in only 2 clinical trials, the first by Scognamiglio
t al. (8), who compared the effects of the calcium antago-
ist nifedipine to that of digoxin in 143 asymptomatic
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Heart Failure Program, Division of Cardiology, Department of Medi-f
ine, University of Southern California, Keck School of Medicine, Los Angeles,
alifornia.atients with chromic, severe AR followed for an average of
years, and reported a significantly superior effect of
ifedipine on delaying progression to AVR. In contrast, a
econd study by Evangelista et al. (9) failed to demonstrate
similar superior effect of nifedipine compared with enala-
ril or even placebo on the rate of progression to AVR in
30 similar patients who were followed for 7 years. These
onflicting results and the relatively small number of pa-
ients included in these studies help to explain the consid-
rable uncertainty regarding the long-term effect of vasodi-
ator and ACE inhibitor therapy in patients with chronic
R (2,3).
The use of beta-blockers in patients with AR has been
raditionally considered relatively contraindicated (2,10)
ecause of their negative inotropic as well as chronotropic
ffects; the latter may lead to prolongation of diastole and
hus to an increase in aortic regurgitant volume. Recent
tudies in animals with chronic AR have shown, however, a
avorable effect of beta-blockers in the prevention of LV
ilation and preservation of LV ejection fraction and filling
arameters (11), as well as decreased LV subendocardial
brosis and even prolongation of survival (12).
In this issue of the Journal, Sampat et al. (13) published
retrospective observational study that demonstrated a
otential survival benefit of beta-blockers in patients with
evere AR. The study included 756 patients that were
dentified from the investigators’ institutional echocardio-
raphic database between 1993 to 2007. The average age
as 61  18 years, 59% were men, and the mean LV
jection fraction was 54  19%. Over a period of 4.4  4.1
ears, patients who were treated with beta-blockers for at
east 1 month had a significantly better survival of 90% and
0% at 1 and 5 years, respectively, compared with patients
ot treated with beta-blockers (75% and 55%, respectively,
 0.0009). The beneficial effect of beta-blockers was seen in
atients with and without known coronary artery disease and
ith and without a history of hypertension. Analysis of the
ffect of beta-blockers in subgroups of the study population
tratified by heart rate demonstrated that the effect of therapy
as limited to patients with higher heart rates. What are the
linical implications of this study? Unfortunately, and similar to
ther retrospective studies, this analysis suffers from major
imitations that include a heterogeneous patient population
patients with and without AVR, coronary artery disease, and
ypertension, as well as patients with variable degrees of LV
unction). In addition, because of its retrospective design, the
aper cannot provide information on the type and dose of the
eta-blocking agents used, nor on concomitant therapy. Al-
hough propensity score analysis was appropriately performed
n an attempt to adjust for comorbidities and covariate imbal-
nces between the beta-blockers and the comparison groups,
his method of analysis cannot completely rule out potential
election bias. Because it is not possible to identify and adjust
or all possible factors, differences between those patients who
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July 28, 2009:458–9 Beta-Blockers and Aortic Regurgitationere treated with beta-blockers and those who were not cannot
e completely excluded. These differences include age, inci-
ence of coronary artery disease and hypertension, heart rate,
V end-diastolic dimension, presence of LV hypertrophy,
oncomitant medications, rate of AVR, and coronary artery
ypass grafting. In addition, treatment must have started at
arious times during the study period, leading to potential
nception time bias.
Because of these limitations, the results of the study can
nly be considered as hypothesis generating rather than
vidence that can change clinical practice. Despite these
imitations, the relatively large number of patients with
evere AR included in the analysis as well as the consistent
enefits demonstrated with beta-blocker therapy, both in
he entire group as well as in important subgroups, are
mpressive and may provide clinically important informa-
ion. My own conclusions based on the results of the study
re that the recommendations (which have not been based
n clinical evidence) not to use beta-blockers in patients
ith AR should be removed. The use of beta-blockers in
atients with AR for the treatment of other conditions such
s hypertension, arrhythmias, and coronary artery disease
eems reasonable and may be beneficial. The encouraging
esults of this study should provide a strong incentive for
nvestigators to design, and for funding institutions to
upport, a large, prospective and randomized study aimed at
valuating the therapeutic effect of beta-blockers in the
reatment of patients with clinically significant AR.
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